Uncategorized
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.